Edwards Lifesciences Corp

Latest Results (04.09.2025):

Edwards Lifesciences Corp reported strong financial performance for the third quarter of 2023, highlighting robust sales growth and strategic product advancements. The company achieved double-digit sales increases across its key segments and reaffirmed its full-year growth guidance, demonstrating continued confidence in its innovation-driven strategy.

Revenue Growth

In Q3 2023, Edwards Lifesciences reported total sales of $1.48 billion, marking a 12% increase compared to the same quarter last year. On a constant currency basis, sales grew by 11%, reflecting steady global demand for the company’s advanced heart disease and critical care solutions.

Transcatheter Aortic Valve Replacement (TAVR) Performance

TAVR sales reached $961 million in Q3 2023, an 11% year-over-year increase and 10% growth on a constant currency basis. The success was driven by the continued adoption of the SAPIEN 3 Ultra RESILIA valve, positioning TAVR as a leading treatment for aortic valve failure with expectations of a $10 billion opportunity by 2028.

Earnings Per Share (EPS)

The company reported earnings per share of $0.63 for the third quarter, with adjusted EPS of $0.59. These results underscore Edwards Lifesciences' ability to maintain profitability while investing in growth and innovation.

Product Approvals and Innovations

Edwards Lifesciences achieved significant milestones with multiple product approvals, including the CE Mark for EVOQUE, the first transfemoral tricuspid replacement system, and the PASCAL Precision system in Japan. Additionally, the company completed pivotal trial enrollment for its SAPIEN M3 mitral replacement system, reinforcing its leadership in transcatheter therapies.

Financial Outlook

The company reiterated its full-year 2023 guidance, expecting constant currency sales growth of 10 to 13 percent. For the fourth quarter, Edwards projects total sales between $1.45 and $1.53 billion and diluted EPS between $0.60 and $0.66, reflecting sustained growth momentum.